The Lymphoma Program at Washington University is internationally recognized for its outstanding patient care and innovative research.
Our team of physicians and healthcare professionals is highly trained and highly experienced. We employ state of the art techniques, including sophisticated pathology and imaging to accurately diagnose, stage, and treat the many different kinds of lymphoma. We emphasize novel treatments and clinical trials to insure optimal outcomes for our patients. The lymphoma team was recently awarded a prestigious SCOR grant (Specialized Center of Research) from the Leukemia and Lymphoma Society, which is a testament to our programs strength and innovation.
Make an Appointment
Please call 314-747-1171 to schedule an appointment with our one of our Lymphoma experts.
Make a gift to Lymphoma Research
Lymphomas and Related Diseases
Our team focuses on the diagnosis and treatment of all types of non-Hodgkin lymphoma (over 100 subtypes), Hodgkin Lymphoma, and Chronic Lymphocytic Leukemia. We perform over 750 new patient consults a year. The most common lymphomas diagnosed and treated by our team include:
- Diffuse Large B Cell Lymphoma
- Follicular Lymphoma
- Marginal Zone Lymphoma
- Mantle Cell Lymphoma
- T Cell Lymphoma (nodal and skin types)
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Our Treatment Approach
The treatment approach is tailored to the individual patient and dependent upon patient and disease specific factors. We work closely with our hematopathology colleagues to ensure an accurate diagnosis, which is critically important when managing lymphoma. We interact regularly with our radiology colleagues to obtain optimal imaging, resulting in correct staging. The treatment will depend largely on the lymphoma subtype and could involve immunotherapy, chemotherapy, novel targeted agents, radiation approaches, stem cell transplantation, cellular therapy with chimeric antigen receptor engineered T cells or some combination of these approaches.
All new consults are discussed as a team and any cases with unusual features are discussed at our weekly multidisciplinary case conference, which includes faculty representation from lymphoma, pathology, radiology, radiation oncology, and stem cell transplantation. Many patients are eligible for cutting edge clinical trials, which will be offered as one of the treatment options. Our team also includes advanced practice providers (nurse practitioners and physician assistants) as well as nurse coordinators with special expertise in lymphomas.
Brad Kahl, MD
Dr. Kahl is the Director of the Lymphoma Program. He cares for patients with all types of lymphoma with clinics at the Center for Advanced Medicine and Siteman South County. His research focuses on developing new and better ways to treat lymphomas using targeted agents. He has particular research interest in Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia.
Nancy Bartlett, MD
Dr. Bartlett care for patients with all types of lymphoma with clinics at the Center for Advance Medicine and Siteman West County. Her research focuses on developing new and better ways to treat all types of lymphomas and she has particular research interest in Diffuse Large B Cell Lymphoma and in Hodgkin Lymphoma.
Amanda Cashen, MD
Dr. Cashen’s clinical practice focuses on stem cell transplantation and CART cell therapy for lymphoma patients with clinics at the Center for Advanced Medicine. Her research interests center on innovative cellular therapy strategies for lymphoma patients.
Todd Fehniger, MD, PhD
Dr. Fehniger’s clinical practice focuses on stem cell transplantation and CART cell therapy for lymphoma patients with a clinic at the Center for Advanced Medicine. His research program is laboratory based and focuses on the biology of natural killer (NK) cells and how to harness NK cells for fighting cancer.
Armin Ghobadi, MD
Dr. Ghobadi’s clinical practice focuses on stem cell transplantation and CART cell therapy for lymphoma patients with clinics at the Center for Advanced Medicine and Siteman South County. His research interests center on innovative cellular therapy strategies for lymphoma patients.
Neha Mehta Shah, MD
Dr. Mehta Shah cares for patients with all types of lymphoma with an emphasis on the management of patients with T cell lymphomas. Her clinics are located at the Center for Advance Medicine and Siteman West County. Her research emphasis is on developing new and better ways to treat patients with T cell lymphomas.
Dilan Patel, MD
Dr. Patel cares for patient with all types of lymphoma and has clinics located at Siteman North County and Siteman Shiloh, IL. His research focuses on immunotherapy for treating blood cancers.
David Russler-Germain, MD, PhD
Dr. Russler-Germain cares for patients with all types of lymphoma and has a clinic at the Center for Advanced Medicine. His research program is laboratory based and focuses on the genomics of lymphoma with a special focus on follicular lymphoma.
- Holly Comer
- Melissa Edwards
- Nina Fragale
- Mandy Piela
- Katy Stewart
- Ashleigh Wesselschmidt
- Monica Cross
- Jacquelyn Hollaway
- Nicki McFerren-Wells
- Lisa Millay
- Susan O’Rando
- Laura Verstrater
- Collen Wagner
- Susan Young
Research and Clinical Trials
The Washington University/Siteman Cancer Center Lymphoma Program recognizes that outcomes for lymphoma patients can be improved through innovative and impactful research. Clinical trials are the cornerstone of our research program. Virtually every new drug and new therapy developed for lymphoma in the past 25 years was tested at our center prior to FDA approval. We have highly innovative cellular therapy programs which harness the power of the immune system in fighting lymphoma. Partnering with our clinical research program are outstanding basic science and translational research programs designed to improve our understanding of lymphoma biology, lymphoma immunology, and lymphoma genomics.
Ongoing Clinical Trial Highlights
- A phase II study evaluating the efficacy of mosunutuzumab in combination with polatuzumab vedotin in untreated follicular lymphoma.
- A phase II study evaluating the safety and efficacy of Glofitamab in combination with R-CHOP in circulating tumor DNA high risk patients with untreated diffuse large B cell lymphoma.
- A randomized phase II study of CHO(E)P vs. CHO(E)P + CC-486 vs. CHO(E)P + duvelisib in untreated CD30 negative PTCL.